Earlier treatment with baricitinib improves quality of life and reduces damage

Share Button

baricitinib, rheumatoid arthritis drug, arthritis digestOnce again, early treatment of rheumatoid arthritis has shown to be key… this time with baricitinib under the spotlight.

Experts found that people with moderate to severe rheumatoid arthritis experienced onset of efficacy sooner when treatment with baricitinib started earlier versus later, but in the end both groups enjoyed similar reductions in disease activity.

Baricitinib is a JAK inhibitor that interferes with the inflammatory processes within the immune system that lead to the symptoms of rheumatoid arthritis. It is a long-term treatment; most people notice an improvement in symptoms within four weeks of starting treatment.

“While overall disease activity improvement was similar, early start of baricitinib treatment provided faster efficacy,” the researchers explain. “A delay of up to six months in baricitinib treatment had an impact on health assessment questionnaire disability index and structural damage progression.”

Arthritis Digest Magazine was selected by Feedspot as one of the Top 5 Arthritis Blogs on the internet in 2018.

For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.

“Amazing magazine and the first I’ve read from beginning to end.” Mrs E Crowther, Dorset

“There’s so much news and information to digest, and it’s all calorie free. Brilliant!” A Alexander, Glasgow
“As we are all living longer, it gives us hope for a future with less pain. Arthritis Digest gives us information on the up to date treatments.”Mrs Healey, Devon
“Full of interesting information and tips.” Mr G Thurlow, East Yorkshire

Google+ | Privacy Policy | FTC Disclaimer

Copyright © 2013. All Rights Reserved.